Logotype for Xeris Biopharma Holdings Inc

Xeris Biopharma Holdings (XERS) investor relations material

Xeris Biopharma Holdings H.C. Wainwright 27th Annual Global Investment Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Xeris Biopharma Holdings Inc
H.C. Wainwright 27th Annual Global Investment Conference summary9 Sep, 2025

Business performance and growth outlook

  • Achieved adjusted EBITDA positivity last year and maintains strong 85% gross margins, supporting self-funded growth.

  • Revenue growth is driven by three key products: Gvoke®, Keveyis®, and Recorlev®, with Recorlev® identified as the largest and fastest-growing.

  • Recorlev® targets a billion-dollar market opportunity, fueled by increased screening for hypercortisolemia and Cushing's syndrome.

  • Commercial footprint is scaling in line with market growth, with ongoing investments planned through 2027 to support expansion.

  • Capital deployment focuses on maximizing ROI, prioritizing Recorlev® and pipeline asset XP8121, leveraging strong revenue and margin profile.

Product pipeline and innovation

  • XP8121, a once-weekly subcutaneous levothyroxine, is phase 3-ready and targets patients with GI absorption issues, addressing a significant unmet need.

  • Phase 3 trial for XP8121 will be a one-year, non-inferiority study with at least 1,000 patients, aiming for robust clinical and payer-relevant data.

  • XP8121 is estimated as a $1–3 billion market opportunity, with innovation expected to drive payer acceptance due to unmet needs.

  • Gvoke® continues to grow in the diabetes market, focusing on education and guideline compliance, with long-term double-digit growth expected.

  • Keveyis® remains resilient despite generic competition, consistently adding new and returning patients in the ultra-rare disease segment.

Market dynamics and competitive positioning

  • Recorlev®'s unique mechanism of action allows for gradual cortisol reduction, differentiating it from competitors that block at the receptor level.

  • Increased screening and detection in the market are seen as positive, expanding the overall opportunity and not posing a significant threat.

  • Commercial investments are ongoing to support both short- and long-term growth, including sales, patient services, and reimbursement support.

  • Payer strategy for XP8121 includes targeting patients with multiple TSH tests out of range, leveraging clinical evidence to address reimbursement challenges.

  • The company leverages its technology and experience in drug-device combinations to support new product launches in endocrinology.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Xeris Biopharma Holdings earnings date

Logotype for Xeris Biopharma Holdings Inc
Q3 20257 Nov, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Xeris Biopharma Holdings earnings date

Logotype for Xeris Biopharma Holdings Inc
Q3 20257 Nov, 2025

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Xeris Biopharma Holdings Inc. is a pharmaceutical company focused on developing and commercializing innovative therapies for patients with endocrine and metabolic disorders, as well as other conditions requiring injectable treatments. The company's technology platform enables the formulation of ready-to-use injectable medications that do not require reconstitution, refrigeration, or complex preparation. The company is headquartered in Chicago, Illinois, and its shares are listed on the NASDAQ.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage